- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06036381
Spatial and Temporal Characterization of Gliomas Using Radiomic Analysis (GLIO-RAD)
April 1, 2024 updated by: Dr Archya Dasgupta, Tata Memorial Centre
Glioma are type of primary brain tumors arising within the substance of brain.
Different type of gliomas are seen which are classified depending upon pathological examination and advanced molecular techniques, which help to determine the aggressiveness of the tumor and outcomes.
Artificial intelligence uses advanced analytical process aided by computer which can be undertaken on the medical images.
We plan to use artificial intelligence techniques to identify the abnormal areas within the brain representing tumor from the radiological images.
Also, similar approach will be undertaken to classify gliomas with good or bad prognosis, to differentiate glioma from other type of brain tumors, and to detect response after treatment.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
In the proposed retrospective study, images (MRI, CT, or PET) undertaken as part of standard of care (pre-treatment, post-operative, response assessment, and surveillance) will be analyzed.
The DMG database maintaining records of patients registered in TMC neuro-oncology DMG will be screened to identify the patients eligible for the study.
With approximately 500-600 gliomas seen annually and approximately 80-100 patients/year having pre-treatment imaging, we expect a ceiling of 1000 patients during 2010-2022, which will be the maximum number of patients used for the analysis.
All the images will be downloaded from the PACS applying anonymization filters, with clinical records extracted by review of electronic medical records and radiation plans.
Imaging pre-processing will be done, which will include skull stripping and registration across different modalities (e.g., MRI and CT) or different sequences (e.g., T1C, T2W, ADC) will be done using rigid or deformable algorithms as suited best for the modality.
Image segmentation to classify the region of interest will be done and verified individually by a neuro-radiologist or nuclear medicine physician as appropriate.
The segmentations will be done to identify T1-contrast enhancing region (CE), non-enhancing regions (NE), and necrosis (NEC) guided by T1-C, T2W, and T2-FLAIR areas.
The contours and the images will be resampled to a uniform resolution for different sequences or modalities (e.g., T2W/ ADC/ PET) to match either with the 3D sequence (e.g., FSPGR sequence) or available images with the least slice thickness.
Subsequently, normalization techniques (e.g., histogram normalization/ Z-score normalization) will be undertaken within the individual images and across the entire dataset to account or image heterogeneity, including field strength for MRI and different image acquisition parameters.
For auto segmentation, both supervised and unsupervised machine learning algorithms will be applied.
For the supervised model, the entire database will be split into training and test cohorts for the model and application development, respectively.
The effectiveness of the automated model will be tested using the dice similarity coefficient between manually segmentation regions and AI-based segments.
For prognostication of gliomas, the next step will include feature extraction, which will consist of first-order (including shape, histogram), second-order or higher-order (e.g., different texture features like GLCM, GLDM, GLSZM, etc.), or deep learning techniques will be employed.
Delta-radiomics will include temporal changes in the radiomic features from different time points for the same patient within the entire volume and individual regions.
Subsequently, feature reduction and selection techniques like LASSO, recursive feature elimination will be used to shortlist the number of features depending on the sample size.
The outputs will be decided based on the modeling defined for specific class problems (e.g., tumor vs. edema, recurrence vs. pseudo progression, outcomes, tumor region of interest vs. non-tumoral area) as obtained from the clinical information.
Any class imbalance will be addressed using methods like random subset sampling or SMOTE analysis for data augmentation of the minority class.
Machine learning algorithms like LDA, k-NN, SVM, random forest, AdaBoost, etc., will be applied singularly or in combination as an ensembled classifier to find the model with best performance.
Deep learning classifiers will be used along with feature-based modeling and compared to test the classifier's applicability.
Validation techniques like leave-one-out validation, k-fold validation, and split (into training and test cohort) will be used to assess the stability of the machine learning model.
Radiomic analysis will be done by data scientist/ study investigators with expertise in data analytics.
All segmentations will be done on open-source software like ITK snap (itksnap.org)
or 3D Slicer (slicer.org).
Feature extraction and modeling will be done using open-source software like Python (python.org).
With continuous advancements in computational science, available newer analytical techniques and platforms will be applied as appropriate by collaborators from Indian Statistical Institute, Kolkata, Machine Intelligence Unit by sharing of the anonymized data.
Study Type
Observational
Enrollment (Estimated)
1000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Dr. ARCHYA DASGUPTA, MD
- Phone Number: 6861 022-24177000
- Email: archya1010@gmail.com
Study Locations
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400012
- Tata Memorial Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Study population will be according to the Inclusion and Exclusion Criteria .
Study Includes vulnerable participants also.
Minors (up to 18 years),Elderly
Description
Inclusion Criteria:
- Patients with glioma or glioma-mimicking pathology with imaging available in TMC between January 2010 and December 2022.
Exclusion Criteria:
- Imaging done outside TMC.
- Motion artifacts or other artifacts causing image degradation.
- Size of tumor or region of interest < 1 cm in the largest dimension
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Autosegmentation of tumor
Time Frame: 3 years
|
The correlation of tumor region between manual segmentation and artificial intelligence-based autosegmentation model will be assessed using the Dice coefficient of similarity.
|
3 years
|
Prognostication of gliomas
Time Frame: 3 years
|
Radiomic signature in prognostication of gliomas with estimation of progression-free survival and overall survival using Kaplan Meier plots and radiomics score-based nomograms.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response assessment in gliomas
Time Frame: 3 years
|
Response assessment of gliomas using artificial intelligence model-based prediction and comparison with actual response (like radionecrosis, progression) using confusion matrices and estimation of parameters like sensitivity, specificity, accuracy, area under curve.
|
3 years
|
Differentiation of glioma from non-glioma histology
Time Frame: 3 years
|
Use of radiomics model to differentiate gliomas from other brain tumors, with performance indices calculated using sensitivity, specificity, accuracy, area under curve.
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Dr. ARCHYA DASGUPTA, MD, Tata Memorial Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 15, 2024
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2026
Study Registration Dates
First Submitted
August 28, 2023
First Submitted That Met QC Criteria
September 6, 2023
First Posted (Actual)
September 13, 2023
Study Record Updates
Last Update Posted (Actual)
April 2, 2024
Last Update Submitted That Met QC Criteria
April 1, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4146
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioma
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationNot yet recruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma IntracranialUnited States
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics, Inc; Dragon Master FoundationRecruitingGlioma | High Grade Glioma | Glioma, Malignant | Diffuse Glioma | Glioma IntracranialUnited States
-
ChimerixActive, not recruitingGlioblastoma | Diffuse Midline Glioma | H3 K27M Glioma | Thalamic Glioma | Infratentorial Glioma | Basal Ganglia GliomaUnited States
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II GliomaUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
Beijing Tiantan HospitalDuke UniversityUnknownGlioblastoma | High Grade Glioma | Glioma, Malignant | Glioma of BrainstemChina
-
Hospital del Río HortegaCompletedGlioma | Glioblastoma | Low-grade Glioma | Glioma, Malignant | High-grade GliomaSpain
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGlioblastoma | Malignant Glioma | WHO Grade III Glioma | Recurrent Glioma | Refractory GliomaUnited States
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Grade III Glioma | Grade III GliomaUnited States, Australia, Israel, Switzerland
Clinical Trials on Radiomic analysis of imaging - MRI, PET, CT
-
University Hospital, Basel, SwitzerlandSwiss Foundation for the Study of Muscular DiseasesCompletedGiant Cell Arteritis | Large Vessel Giant Cell ArteriitisSwitzerland
-
University of CincinnatiActive, not recruiting
-
Gert MeijerM.D. Anderson Cancer CenterCompletedEsophageal CancerUnited States, Netherlands
-
University of CambridgeCambridge University Hospitals NHS Foundation Trust; Wellcome TrustRecruitingMyocardial Infarction | Coronary Artery Disease | Inflammation | AtherosclerosisUnited Kingdom
-
Imperial College LondonBiogen; InvicroCompletedInflammatory Response | Stroke, Ischemic | Stroke, AcuteUnited Kingdom
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingCritical Illness | Emergency Medical Services | Machine Learning | Diagnosis | Emergency Service, HospitalChina
-
Institute of Cancer Research, United KingdomRoyal Marsden NHS Foundation Trust; National Institute for Health Research,...Completed
-
Robert Flavell, MD, PhDUnited States Department of Defense; Fortis Therapeutics, Inc.RecruitingProstate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Ottawa Hospital Research InstituteCanadian Institutes of Health Research (CIHR)Active, not recruiting
-
Copenhagen University Hospital at HerlevUnknown